scholarly journals Post‐treatment clinical course following botulinum toxin injection therapy for adductor spasmodic dysphonia: Analysis of data from a placebo‐controlled, randomized, double‐blinded clinical trial in Japan

2021 ◽  
Author(s):  
Kahori Hirose ◽  
Kento Asano ◽  
Masahiko Sakaguchi ◽  
Asuka Nagao ◽  
Maya Nakahira ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Botulinum Toxin ◽  
Clinical Course ◽  
Botulinum Toxin Injection ◽  
Post Treatment ◽  
Injection Therapy ◽  
Spasmodic Dysphonia ◽  
Adductor Spasmodic Dysphonia ◽  
Double Blinded

Adductor spasmodic dysphonia: case reports withacoustic analysis following botulinum toxin injection and acupuncture

1997 ◽  
Vol 11 (2) ◽  
pp. 232-237 ◽  
Author(s):  
Lise Crevier-Buchman ◽  
Ollivier Laccourreye ◽  
Jean-François Papon ◽  
Dominique Nurit ◽  
Daniel Brasnu
Keyword(s):  
Botulinum Toxin ◽  
Case Reports ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Adductor Spasmodic Dysphonia

scholarly journals Treatment Efficacy of Electromyography versus Fiberscopy-Guided Botulinum Toxin Injection in Adductor Spasmodic Dysphonia Patients: A Prospective Comparative Study

2014 ◽  
Vol 2014 ◽  
pp. 1-4 ◽  
Author(s):  
Jae Wook Kim ◽  
Jae Hong Park ◽  
Ki Nam Park ◽  
Seung Won Lee
Keyword(s):  
Botulinum Toxin ◽  
Treatment Efficacy ◽  
Botulinum Toxin Injection ◽  
Spasmodic Dysphonia ◽  
Total Dosage ◽  
Adductor Spasmodic Dysphonia ◽  
Prospective Comparative Study ◽  
The Mean ◽  
Botulinum Toxin Injections ◽  
The Voice

Introduction. This study prospectively evaluates and compares the treatment efficacy of botulinum toxin injection under electromyography guidance (EMG group) and percutaneous botulinum toxin injection under flexible fiberscopic guidance (fiberscopy group).Methods. Thirty patients with adductor spasmodic dysphonia (ADSD), who had never received treatment, were randomly allocated into EMG- or fiberscopy-guided botulinum toxin injections between March 2008 and February 2010. We assessed acoustic and aerodynamic voice parameters, and the voice handicap index (VHI) before injection and at 1, 3, and 6 months after injection.Results. The mean total dosage of botulinum toxin was similar for both groups: 1.7 ± 0.5 U for the EMG group and 1.8 ± 0.4 U for the fiberscopy group (P>0.05). There were no significant differences in outcomes between the two groups in either the duration of effectiveness or complications such as breathy voice and aspiration.Conclusion. Botulinum toxin injection under fiberscopic guidance is a viable alternative to EMG-guided botulinum toxin injection for the treatment of adductor spasmodic dysphonia when EMG equipment is unavailable.

Point-Touch Technique of Botulinum Toxin Injection for the Treatment of Spasmodic Dysphonia

1992 ◽  
Vol 101 (11) ◽  
pp. 883-887 ◽  
Author(s):  
David C. Green ◽  
Paul H. Ward ◽  
Gerald S. Berke ◽  
Bruce R. Gerratt
Keyword(s):  
Botulinum Toxin ◽  
Botulinum Toxin Injection ◽  
Current Method ◽  
Spasmodic Dysphonia ◽  
Needle Placement ◽  
Careful Evaluation ◽  
Anatomic Landmarks ◽  
Adductor Spasmodic Dysphonia ◽  
Botox Injection ◽  
Thyroarytenoid Muscle

Intralaryngeal injections of botulinum toxin (Botox), under electromyographic guidance, have emerged as an effective treatment for adductor spasmodic dysphonia. To remain effective, these injections must be repeated every 3 to 9 months as the symptoms recur. One drawback to the current method is the need for electromyographic confirmation of needle placement into the thyroarytenoid muscle. This report describes an anatomic approach to Botox injection that requires only flexible nasopharyngeal endoscopy and careful evaluation of the anatomic landmarks. This technique has been used successfully on 13 patients, and objective pretreatment and posttreatment measures are reported.

Sign in / Sign up

Export Citation Format

Share Document